Viewing Study NCT04214067


Ignite Creation Date: 2025-12-25 @ 12:40 AM
Ignite Modification Date: 2025-12-25 @ 10:51 PM
Study NCT ID: NCT04214067
Status: ACTIVE_NOT_RECRUITING
Last Update Posted: 2025-11-12
First Post: 2019-12-27
Is NOT Gene Therapy: False
Has Adverse Events: False

Brief Title: Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to the Usual Radiation Treatment for Newly Diagnosed Early Stage High Intermediate Risk Endometrial Cancer
Sponsor: National Cancer Institute (NCI)
Organization:

Study Modules

Identification Module Status Module Sponsor Collaborators Module Oversight Module Description Module Conditions Module Design Module Arms Interventions Module Outcomes Module Eligibility Module Contacts Locations Module References Module